Compare WKHS & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKHS | GRML |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 34.9M |
| IPO Year | 2008 | 2022 |
| Metric | WKHS | GRML |
|---|---|---|
| Price | $2.72 | $0.19 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 95.7K | ★ 7.6M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $763,173.00 | N/A |
| Revenue This Year | $89.23 | N/A |
| Revenue Next Year | $28.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.16 |
| 52 Week High | $11.80 | $0.55 |
| Indicator | WKHS | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 41.63 |
| Support Level | $2.63 | $0.16 |
| Resistance Level | $3.34 | $0.34 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 53.36 | 27.86 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.